Related references
Note: Only part of the references are listed.Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped
Edouard Louis et al.
GASTROENTEROLOGY (2012)
Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission
Kofi Clarke et al.
INFLAMMATORY BOWEL DISEASES (2012)
Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapy
S. Danese et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay: authors' reply
C. Steenholdt et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease
C. Steenholdt et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Review article: infliximab for Crohn's disease treatment - shifting therapeutic strategies after 10 years of clinical experience
S. Danese et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study
D. Laharie et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response
Geert R. D'Haens et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease
Nicholas J. Talley et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Assessing Response and Loss of Response to Biological Therapies in IBD
Henit Yanai et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
The immunogenic part of infliximab is the F(ab ')(2), but measuring antibodies to the intact infliximab molecule is more clinically useful
Shomron Ben-Horin et al.
GUT (2011)
Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease
Casper Steenholdt et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2011)
Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort
A. W. G. Waugh et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Anti-TNF and Crohn's Disease: When Should We Stop?
Edouard Louis et al.
CURRENT DRUG TARGETS (2010)
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
A. Dignass et al.
JOURNAL OF CROHNS & COLITIS (2010)
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects
Matthieu Allez et al.
JOURNAL OF CROHNS & COLITIS (2010)
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
Javier P. Gisbert et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
F. Schnitzler et al.
GUT (2009)
Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease
Mark A. Ainsworth et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
European evidence-based Consensus on the management of ulcerative colitis: Current management
S. P. L. Travis et al.
JOURNAL OF CROHNS & COLITIS (2008)
Is the efficacy of successful infliximab induction therapy maintained for one year lasting without retreatment in different behavior types of Crohn's disease?
T. Molnar et al.
JOURNAL OF CROHNS & COLITIS (2008)
Clinical course in Crohn's disease: Results of a Norwegian population-based ten-year follow-up study
Inger Camilla Solberg et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
American Gastroenterological Association Consensus Development Conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006
M. Clark et al.
GASTROENTEROLOGY (2007)
Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab:: how long should patients be treated?
E Domènech et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial
RJ Farrell et al.
GASTROENTEROLOGY (2003)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Share Paper
